IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland
Open Access
- 11 September 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (18) , 2910
Abstract
IVDR regulation represents a major challenge for diagnostic microbiology laboratories. IVDR complicates a broad range of aspects and poses a risk given the high diversity of pathogens (including rare but highly virulent microbes) and the large variety of samples submitted for analysis. The regular emergence of new pathogens (including Echovirus E-11, Adenovirus 41, Monkeypox virus, Alongshan virus, and Enterovirus D68, as recent examples in Europe in the post SARS-CoV-2 era) is another factor that makes IVDR regulation risky, because its detrimental effect on production of in-house tests will negatively impact knowledge and expertise in the development of new diagnostic tests. Moreover, such regulations negatively impact the availability of diagnostic tests, especially for neglected pathogens, and has a detrimental effect on the overall costs of the tests. The increased regulatory burden of IVDR may thereby pose an important risk for public health. Taken together, it will have a negative impact on the financial balance of diagnostic microbiology laboratories (especially small ones). The already-high standards of quality management of all ISO-accredited and Swissmedic-authorized laboratories render IVDR law of little value, at least in Switzerland, while tremendously increasing the regulatory burden and associated costs. Eventually, patients will need to pay for diagnostic assays outside of the framework of their insurance in order to obtain a proper diagnostic assessment, which may result in social inequity. Thus, based on the risk assessment outlined above, the coordinated commission for clinical microbiology proposes adjusting the IvDO ordinance by (i) introducing an obligation to be ISO 15189 accredited and (ii) not implementing the IvDO 2028 milestone.Keywords
This publication has 19 references indexed in Scilit:
- Overview about Candida auris: What's up 12 years after its first description?Journal of Medical Mycology, 2022
- Lessons from SARS-CoV-2 Pandemic: Evolution, Disease Dynamics and FutureBiology, 2020
- The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complicationsClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Prevalence of the emerging novel Alongshan virus infection in sheep and cattle in Inner Mongolia, northeastern ChinaParasites & Vectors, 2019
- Human MonkeypoxInfectious Disease Clinics of North America, 2019
- Bacterial genome sequencing in clinical microbiology: a pathogen-oriented reviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Comparative genomics of Neisseria meningitidis strains: new targets for molecular diagnosticsClinical Microbiology and Infection, 2016
- Taxogenomics of the order ChlamydialesInternational Journal of Systematic and Evolutionary Microbiology, 2015
- Rapid bacterial genome sequencing: methods and applications in clinical microbiologyClinical Microbiology and Infection, 2013
- High Occurrence of a New Variant of Chlamydia trachomatis Escaping Diagnostic Tests Among STI Clinic Patients in Stockholm, SwedenSexually Transmitted Diseases, 2008